Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05514834 · ClinicalTrials.gov registry record · Early Phase 1

BCT-HA Kit for Dehydrated and Wrinkled Skin

A Early Phase 1 study, sponsored by University of Minnesota.

Completed
Registry status
Early Phase 1
Development phase
15
Enrollment target

NCT05514834 is a Early Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05514834, a Early Phase 1 study, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Early Phase 1
Development phase
15 participants
Enrollment target

Study Summary

This study will assess the efficacy of Cellular MatrixTM BCT-HA Kit treatment compared to placebo condition on revitalization and skin rejuvenation on the midface. Particular attention will be made to the safety aspects, as well as the histological consequences of treatment.

Interventions

  • OTHER Placebo
  • DEVICE Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)
  • OTHER PRP Only

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-06-10
Est. Completion 2024-02-29
Phase Early Phase 1

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT05514834

The ClinicalTrials.gov registry entry for NCT05514834 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT05514834 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05514834 about?

NCT05514834 is a clinical study titled "BCT-HA Kit for Dehydrated and Wrinkled Skin". This study will assess the efficacy of Cellular MatrixTM BCT-HA Kit treatment compared to placebo condition on revitalization and skin rejuvenation on the midface. Particular attention will be made to the safety aspects, as well as the histological consequences of treatment.

What is the current status of trial NCT05514834?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2022-06-10. Estimated completion is 2024-02-29.

What interventions are being tested in trial NCT05514834?

The interventions under investigation include: Placebo (OTHER), Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3) (DEVICE), PRP Only (OTHER).

Who is sponsoring clinical trial NCT05514834?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.